F
FDA
Guest
FDA has granted accelerated approval for Oxbryta (voxelotor) tablets to treat sickle cell disease in pediatric patients aged four up to 11 years. FDA had previously granted accelerated approval for Oxbryta for patients aged 12 years and older with sickle cell disease.
Baca selengkapnya di : http://www.fda.gov...
Baca selengkapnya di : http://www.fda.gov...